BPC-157 acetate vs arginate — salt forms compared
BPC-157 (Body Protection Compound 157) is a 15-amino-acid synthetic peptide; the BPC molecule is identical regardless of salt form. The two commercial forms — acetate (the historical default) and arginate — differ only in the counter-ion paired with the peptide for stability. The arginate salt is more stable across a wider pH range, which matters for research protocols testing oral or sublingual administration where pH fluctuations during transit affect peptide integrity. For standard SC research protocols (where reconstituted peptide is used immediately), the practical difference is minor. Receptor pharmacology — the angiogenesis, NO modulation, growth-hormone-receptor interactions characterised in the published literature — is identical.
Side-by-side
| BPC-157 15 mg | BPC-157 Arginate | |
|---|---|---|
| Peptide | BPC-157 (15 AA) | BPC-157 (15 AA, identical) |
| Counter-ion | Acetate | Arginate |
| pH stability | Narrower window | Wider window |
| Solution stability — refrigerated | ~4 weeks | ~4-6 weeks |
| Theoretical oral absorption | Lower | Higher (debated) |
| Research-grade availability | Long-standing default | Newer; gaining adoption |
| Bioactivity at receptor | Identical to arginate | Identical to acetate |
What to know
- ·Same peptide, different salt — receptor pharmacology is unchanged.
- ·Arginate's stability advantage matters for oral / sublingual research protocols where the peptide must survive transit through pH variations.
- ·For SC research protocols (standard), the two are functionally interchangeable.
- ·Both are research-use only.
- ·Cost is similar; arginate is sometimes slightly more expensive due to lower production volume.
Where the literature diverges
The published BPC-157 research overwhelmingly used the acetate form (the salt form Sikiric's group worked with from the 1990s onwards). Arginate is a more recent commercial development and direct comparative pharmacokinetic studies are limited. Inferences about superior oral bioavailability are extrapolated from peptide chemistry principles rather than head-to-head data.
FAQ
Which salt should I use?+
For SC injection research: either, no meaningful difference. For oral / sublingual research protocols: arginate's stability advantage is theoretically beneficial. The receptor pharmacology is identical; counter-ion choice is a logistics question.
Is BPC-157 active orally?+
Limited evidence. Most published trials use SC or IM. Some animal-model studies show oral bioavailability via local gut effects (the 'body protection' nomenclature comes from gastrointestinal protection studies), but systemic effects from oral dosing are weakly characterised. For research designs requiring systemic effects, parenteral routes are standard.
This is a research-context comparison of compound mechanism and published trial outcomes. Not medical advice. Both compounds are research-use only when sold by Omega Grade — for in vitro laboratory investigation, not human or veterinary administration.
- ResearchBPC-157 15 mg
15-residue synthetic pentadecapeptide. Most extensively studied in rodent tendon, ligament, skin, and gastric-mucosal models.
- ResearchBPC-157 + TB-500 10/10 mg kit
The most-requested regenerative-peptide kit in the catalogue. BPC-157 and thymosin β-4 combined in a single lyophilised vial — commonly paired in prec
- ResearchTB-500 10 mg
Synthetic full-length 43-residue thymosin β-4. The most abundant intracellular actin-sequestering peptide in mammalian tissues.
- Biomarkerhs-CRP 2.5 mg/L
High-sensitivity C-reactive protein at 2.5 mg/L sits in the 'intermediate cardiovascular risk' category most cardiology research uses. What it measures, what drives it, and how to interpret your number.
- ComparisonBPC-157 vs TB-500 — research differences and combined-use literature
BPC-157 and TB-500 (thymosin beta-4 fragment) are the two most-studied research peptides in tissue-repair literature. Their mechanisms differ — what the research shows, and why they're often paired in protocol papers.